Caprion Biosciences (Montreal, Canada) and HistoGeneX (Antwerp, Belgium) announce the combination of their businesses creating a leading company focusing on immune monitoring, protein characterization and tissue pathology solutions for immunotherapy and drug development.
The new business merger will provide both immune monitoring and biomarker development services from preclinical to late stage clinical trials. The partnership will offer quantitative mass spectrometry services for proteomic profiling, target quantitative bioanalytical assays, both single and multiplexed immunohistochemistry assays and multiparametric flow cytometry for monitoring immune system responses. The partnership was aided by investment from Arsenal Capital Partners (NY, USA).
Mark Kockx and Dirk Hendriks, co-founders of HistoGeneX, along with Christopher Ung, chief business officer, commented: “We believe there is tremendous potential for the combined entity. We respect Caprion’s scientific expertise and industry reputation for scientific rigor and quality execution and are looking forward to leveraging the combined company’s capabilities to develop the next generation of solutions and services for precision medicine.”
Martin LeBlanc, co-founder of Caprion, explained: “We found a shared vision with the leadership of HistoGeneX and Arsenal to create the global leader in immune monitoring and drug development services and solutions. We look forward to continuing to deliver high quality science and superior service and are very excited about what this combination means for our client partners and employees.”